Verified Nov 2026
Chassis & Safety Systems
·

Radnor, Pennsylvania
·
Since 2003
Marinus Pharma is a biopharmaceutical company founded in 2003 and headquartered in Radnor, Pennsylvania, with 50–100 employees and estimated revenue of $10–50 million. The company develops therapeutics for seizure disorders and neurological conditions, with ZTALMY® (ganaxolone) as its lead FDA-approved product for treating seizures in CDKL5 deficiency disorder. Marinus became a subsidiary of Immedica Pharma AB in February 2025.
Marinus Pharma at a glance
Revenue
$10-50M
Est. band
Employees
50-100
Founded
2003
Headquarters
Radnor, Pennsylvania
Industries
Automotive
Electric Vehicles
Medical
Overview
Marinus Pharma is a biopharmaceutical company founded in 2003 and headquartered in Radnor, Pennsylvania, with 50–100 employees and estimated revenue of $10–50 million. The company develops therapeutics for seizure disorders and neurological conditions, with ZTALMY® (ganaxolone) as its lead FDA-approved product for treating seizures in CDKL5 deficiency disorder. Marinus became a subsidiary of Immedica Pharma AB in February 2025.
At a glance
Attribute | Detail |
|---|---|
Founded | 2003 |
Headquarters | Radnor, Pennsylvania |
Employees | 50-100 |
Revenue | $10-50M (estimated) |
Primary capability | Chassis & Safety Systems |
What Marinus Pharma makes
The company manufactures ganaxolone in oral suspension form and is developing additional formulations including intravenous and capsule options to address seizure disorders across multiple care settings.
Products and capabilities described on the company's own site include Suspension (source: marinuspharma.com).
Latest developments
2025-05-19 — L.O.T.W. #120 - Marinus Pharmaceuticals - Monetizes future revenue stream through revenue interest financing agreement (thecreditbubble.com)
2025-02-11 — Immedica completes acquisition of Marinus Pharmaceuticals, Inc. | Immedica (immedica.com)
2025-02-07 — Immedica successfully completes tender offer for all outstanding shares of common stock of Marinus Pharmaceuticals, Inc. | Immedica (immedica.com)
2025-01-08 — tm252202-1_sctot_DIV_54-exba1d - none - 1.9843752s (sec.gov)
2025-01-06 — Immedica to Acquire Marinus for $151 Million - Global Genes (globalgenes.org)
2025-01-02 — After phase 3 setbacks, troubled Marinus inks $151M sale to Immedica Pharma | Fierce Pharma (fiercepharma.com)
Facilities
Marinus Pharma is headquartered in Radnor, Pennsylvania. Public sources also reference these locations:
Branford, Connecticut — akta.pro
Company details
Marinus serves healthcare providers, caregivers, and patients with seizure and neurological conditions, and operates a facility in Branford, Connecticut in addition to its Pennsylvania headquarters. Marinus Pharma was founded in 2003, has an estimated 50-100 employees, and is headquartered in Radnor, Pennsylvania.
Frequently asked questions
What does Marinus Pharma make?
Marinus Pharma is a biopharmaceutical company founded in 2003 and headquartered in Radnor, Pennsylvania, with 50–100 employees and estimated revenue of $10–50 million. The company develops therapeutics for seizure disorders and neurological conditions, with ZTALMY® (ganaxolone) as its lead FDA-approved product for treating seizures in CDKL5 deficiency disorder. Marinus became a subsidiary of Immedica Pharma AB in February 2025.
Where is Marinus Pharma headquartered?
Marinus Pharma is headquartered in Radnor, Pennsylvania (100 Matsonford Road, Radnor, Pennsylvania, 19087).
When was Marinus Pharma founded?
Marinus Pharma was founded in 2003.
How big is Marinus Pharma?
Marinus Pharma has an estimated 50-100 employees, with revenue in the $10-50M range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
